UBS Raised the Firm’s PT on LifeStance Health Group (LFST), Kept a Buy Rating

LifeStance Health Group, Inc. (NASDAQ:LFST) is one of the Best 52-Week Low Penny Stocks to Buy NowOn August 8, UBS raised the firm’s price target for LifeStance Health Group, Inc. (NASDAQ:LFST) from $8.50 to $9, while maintaining a Buy rating on the stock.

The increased price target follows the company’s fiscal second-quarter earnings release. The company exceeded both revenue and earnings estimates during the quarter. LifeStance Health Group, Inc. (NASDAQ:LFST) posted a revenue of $345.31 million, reflecting a 10.56% year-over-year growth and ahead of estimates by $58,730. Moreover, the EPS of negative $0.01 also beat the analyst consensus by $0.02.

UBS Raised the Firm’s PT on LifeStance Health Group (LFST), Kept a Buy Rating

A close-up of a healthcare professional studying a computer screen with data while consulting with a patient.

Management noted that they increased the number of clinicians providing care by 11% year-over-year, which led to a 12% increase in visit volumes during the quarter. Looking ahead, management has reaffirmed its full-year revenue guidance in the range of $1.40 billion to $1.44 billion.

LifeStance Health Group, Inc. (NASDAQ:LFST) is a reimagining mental health company that provides both virtual and in-person mental healthcare for children, adolescents, and adults.

While we acknowledge the potential of LFST to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LFST and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.